We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
TABRECTA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
TABRECTA
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
capmatinib hydrochloride
Registration type
NCE/NBE
Indication
TABRECTA® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation